We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Randox Laboratories

  Platinum Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Urine Testing Differentiates Glomerular from Tubulointerstitial Diseases on Kidney Biopsy

By LabMedica International staff writers
Posted on 22 Apr 2022
Print article
Image: Randox Daytona RX chemical analyzer (Photo courtesy of Gemini BV)
Image: Randox Daytona RX chemical analyzer (Photo courtesy of Gemini BV)

Histological examination of kidney biopsy tissue can help differentiate between glomerular and tubulointerstitial diseases, as well as differentiate between their underlying etiologies and subtypes.

Several clinical urine tests are available to differentiate between glomerular and tubulointerstitial diseases. Clinically available tests include urinalysis, urine sediment microscopy, and urine albumin, which can indicate glomerular damage via features such as urinary presence of isomorphic or dysmorphic red blood cells (RBCs) and casts, or presence of proteinuria or albuminuria.

Clinical Scientists at the Yale School of Medicine (New Haven, CT, USA) and their colleagues enrolled patients scheduled to undergo a clinically indicated kidney biopsy at two Yale-affiliated hospitals from January 2015 to June 2018. Urine samples were collected during the outpatient biopsy procedure visit or during inpatient hospitalization. The team performed urine dipstick analysis using Clinitek Status analyzer (Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA) which reported specific gravity, pH, protein, ketone, blood, and leukocyte levels on an ordinal scale.

The team also performed urine sediment microscopy (Laxco LMC4BF, Mill Creek, WA, USA) and took representative pictures at 10× and 40× magnification, which were analyzed and reported by a trained nephrologist on an ordinal scale including RBCs, RBC casts, dysmorphic RBCs, WBCs, WBC casts, renal tubular epithelial (RTE) cells, RTE casts, and granular casts. The investigators measured urine albumin and creatinine measurements using Randox RX Daytona machine (Crumlin, UK) and the other urine biomarkers using manufacturer-validated panels using the Mesoscale Discovery platform (Rockville, MD, USA).

The scientists reported that of the final 359 participants, 121 (34%) had a histological diagnosis of glomerular disease, 89 (25%) had tubulointerstitial disease, and 149 (42%) had mixed glomerular and tubulointerstitial disease. Compared to patients with tubulointerstitial diseases, those with glomerular diseases had more dipstick hematuria (3+ versus 1+) and urine albumin (1.25 versus 0.09 mg/mg). Patients with glomerular diseases had higher levels of tubular health biomarkers (Uromodulin, 1.22 versus 0.92). In a multivariable model, higher urine albumin, dipstick blood, and urine uromodulin were independently associated with higher odds of glomerular diseases (test set AUC, 0.81).

The authors conclude that urine tests, including urine albumin, dipstick blood, and urine uromodulin, was associated with the histological diagnosis of glomerular disease. These findings can help clinicians differentiate between glomerular and tubulointerstitial diseases and guide clinical decisions regarding a kidney biopsy. The study was published on April 11, 2022 in the journal Practical Laboratory Medicine.

Related Links:
Yale School of Medicine 
Siemens Healthcare Diagnostics 
Laxco 
Randox 
Mesoscale Discovery 

Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT
New
Automated Nucleic Acid Extraction System
NuActor
New
Microplate Reader
VANTAstar
New
Benchtop Centrifuge & Vortexer
ExiSpin

Print article

Channels

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.